Swedish researchers have found something counterintuitive in cancer treatment: sometimes less is more. A study of nearly 400 patients with advanced melanoma shows that reducing the dose of immunotherapy drugs not only causes fewer dangerous side effects, but actually produces better tumor control and longer survival.
The findings, published in the Journal of the National Cancer Institute, challenge the assumption that maximum approved doses are always optimal. Patients receiving the lower-dose regimen had a response rate of 49%, compared to 37% in the standard-dose group. The differences in survival were even more striking: median overall survival reached 42 months for the lower-dose patients versus 14 months for those on standard doses.
Why This Works
Malignant melanoma treatment typically combines two immunotherapy drugs: nivolumab and ipilimumab. The catch is that ipilimumab—the more expensive component—carries the heaviest burden of serious side effects. Swedish oncologists have increasingly used a reduced amount of this drug, and the new research suggests that approach is working.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxSerious side effects occurred in 31% of patients on the lower dose, compared to 51% on the standard regimen. This matters because patients who can tolerate treatment longer tend to stay on it longer, which appears to contribute to better outcomes. "The new immunotherapies are very valuable and effective, but they can cause serious side effects that are sometimes life-threatening or chronic," says Hildur Helgadottir, the study's lead researcher at Karolinska Institutet. "Our results suggest that this lower dosage may enable more patients to continue treatment for a longer time."
The advantage of the lower-dose approach held even after accounting for age, tumor stage, and other factors that typically influence outcomes. This wasn't a randomized controlled trial—it was an observational study looking back at how patients fared—so researchers can't definitively say the lower dose caused the improvement. But the pattern is clear enough that it's already changing practice in Sweden, where healthcare systems have more flexibility in adjusting approved drug doses.
In many other countries, reimbursement policies lock treatments into the doses approved by drug authorities, limiting clinicians' ability to experiment. That regulatory rigidity may mean patients elsewhere are receiving higher doses than necessary, experiencing worse side effects for no additional benefit.
The research was conducted with support from Sahlgrenska Comprehensive Cancer Center and funded by Swedish cancer research organizations. The next step is likely to be formal trials that test whether this finding holds across different populations and healthcare systems.
